CATALYST PHARMACEUTICAL PARTNERS, INC. Form 8-K

August 27, 2013

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

# FORM 8-K

#### **CURRENT REPORT**

### PURSUANT TO SECTION 13 OR 15(d) OF

#### THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): August 27, 2013

# CATALYST PHARMACEUTICAL PARTNERS, INC.

(Exact Name Of Registrant As Specified In Its Charter)

**Delaware** (State or other jurisdiction

001-33057 (Commission 76-0837053 (I.R.S. Employer

of incorporation)

File Number)

**Identification No.)** 

## Edgar Filing: CATALYST PHARMACEUTICAL PARTNERS, INC. - Form 8-K


#### 355 Alhambra Circle

**Suite 1500** 

Coral Gables, Florida 33134
(Address of principal executive offices) (Zip Code)
Registrant s telephone number, including area code: (305) 529-2522

#### Not Applicable

Former Name or Former address, if changed since last report



- " Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- " Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR240.14d-2(b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

# Edgar Filing: CATALYST PHARMACEUTICAL PARTNERS, INC. - Form 8-K

#### Item 8.01 Other Events

On August 27, 2013, the Company issued a press release announcing that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to the Company s investigational product, Firdapse, for the symptomatic treatment of patients with Lambert-Eaton Myasthenic Syndrome (LEMS). The press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.

#### Item 9.01 Financial Statements and Exhibits.

- (d) Exhibits
- 99.1 Press Release issued by the Company on August 27, 2013

2

# Edgar Filing: CATALYST PHARMACEUTICAL PARTNERS, INC. - Form 8-K

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Catalyst Pharmaceutical Partners, Inc.

By: /s/ Alicia Grande

Alicia Grande

Vice President, Treasurer and CFO

Dated: August 27, 2013